Market closedNon-fractional
Rezolute/RZLT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Rezolute
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
Ticker
RZLT
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Redwood City, United States
Employees
41
Website
www.rezolutebio.com
Rezolute Metrics
BasicAdvanced
$249M
Market cap
-
P/E ratio
-$1.14
EPS
1.31
Beta
-
Dividend rate
Price and volume
Market cap
$249M
Beta
1.31
Financial strength
Current ratio
11.817
Quick ratio
11.502
Long term debt to equity
2.567
Total debt to equity
3.346
Management effectiveness
Return on assets (TTM)
-34.67%
Return on equity (TTM)
-58.75%
Valuation
Price to book
2.66
Price to tangible book (TTM)
2.66
Price to free cash flow (TTM)
-4.779
Growth
Earnings per share change (TTM)
0.63%
3-year earnings per share growth (CAGR)
-23.57%
What the Analysts think about Rezolute
Analyst Ratings
Majority rating from 7 analysts.
Rezolute Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$0
NaN%
Net income
-$17M
22.30%
Profit margin
0.00%
NaN%
Rezolute Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
-$0.25
-$0.28
-$0.27
-$0.34
-
Expected
-$0.36
-$0.28
-$0.30
-$0.30
-$0.32
Surprise
-29.78%
-0.88%
-10.99%
11.74%
-
Rezolute News
AllArticlesVideos
Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement
GlobeNewsWire·4 weeks ago
Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
GlobeNewsWire·1 month ago
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rezolute stock?
Rezolute (RZLT) has a market cap of $249M as of July 27, 2024.
What is the P/E ratio for Rezolute stock?
The price to earnings (P/E) ratio for Rezolute (RZLT) stock is 0 as of July 27, 2024.
Does Rezolute stock pay dividends?
No, Rezolute (RZLT) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Rezolute dividend payment date?
Rezolute (RZLT) stock does not pay dividends to its shareholders.
What is the beta indicator for Rezolute?
Rezolute (RZLT) has a beta rating of 1.31. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Rezolute stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.